

Keyword Index for Volume 92

- 11 β HSD-1/2 1927
 11p15.5 2216
 17 β -hydroxysteroid dehydrogenase 547
¹⁸F-FDG PET/CT 1046
 1p 1553
 5-aza-2'-deoxycytidine 2024
 5-fluorouracil 24, 259, 634, 722, 832, 1644, 2122
 5-FU 1850
 80 kDa fragment 2018
 acitretin 696
 activation signaling 305
 acute renal failure 480
 acute-phase protein response 673
 ADCC 342
 adenoma 736
 adenovirus 882
 adhesion 729
 adjuvant 24, 843
 adjuvant chemotherapy 259, 2107
 adjuvant radiochemotherapy 1051
 adjuvant therapy 467, 1655
 adrenal incidentalomas 1104
 advanced biliary cancer 1650
 advanced breast cancer 639
 advanced gastric cancer 246, 1644
 advanced ovarian cancer 1019
 Africa 1808
 age 949, 955
 age at births 167
 AIDS 194
 Akt 1711
 alcohol 426
 alcohol dehydrogenase 2039
 alcohol drinking 182
 allelic imbalance 2181
 ALPc_{2a} 2004
 anal cancer 1221
 anaplastic thyroid cancer 1899, 2216
 androgen receptor 140
 aneuploidy 1759
 angiogenesis 89, 94, 1182, 1493, 1696, 1720, 1955
 angiotensin 1247
 anthracyclines 467, 475, 639
 antiangiogenic 1599
 antibiotics 594
 antibody 1430
 antihypertensives 1302
 anti-idiotypic antibodies 1358
 antineoplastic drugs 690
 antisense 532
 antivascular 1599
 anxiety 990, 1393
 apoptosis 120, 328, 359, 513, 681, 705, 736, 1089, 1188, 1247, 1430, 1467, 1593, 1773, 1955, 2185, 2225
 Arg72Pro mutation 1144
 array CGH 1553
 arthroplasty 1298
 asbestos 580
 ascites and metastasis 1475
 ascitic fluid 895
 Ashkenazi Jewish melanoma families 2278
 AT₁ 1247
 atomic force microscopy 1499
 audit 55
 autologous stem cell transplantation 1984
 β 1 integrin 1499
 β 3-integrin expression 41
 β -catenin 1581
 Barrett's metaplasia 888
 basic fibroblast growth factor 705
 BAY 43-9006 1855
 Bcl-2 family 449
 benzo[b]thiophenesulphonamides 690
 Bid 1459
 Bim_{EL} 1773
 bioconjugation 1442
 biological marker 1231
 biomarker 236, 1599
 biotin 1261
 birth interval 167
 bisphosphonates 1869
 bladder 125
 bladder cancer 625, 645, 1276, 1906, 2145, 2153, 2262
 bladder transitional cell carcinoma 80
 BNP7787 1636
 body composition 673
 body shape 2042
 bone marrow 503
 bone pain 1869
 bowel function 1209
 BRAF 2032
 brain metastases 815
 BRCA in men 1288
 BRCA1 857
 breast 60, 613, 618, 949, 955
 breast cancer 47, 55, 147, 167, 201, 225, 231, 342, 382, 467, 547, 553, 594, 597, 634, 906, 1013, 1283, 1293, 1366, 1524, 1531, 1614, 1621, 1720, 1869, 1922, 1948, 1955, 2039, 2049, 2102, 2206
 breast cancer survival 961
 breast carcinoma 120, 156, 631, 1261
 breast neoplasms 2042
 breast neoplasms/pathology 2201
 breast tumours 389
 breast volume 857
 BRG1 1126
 cachexia 1830
 cadherin superfamily 2010
 cadherin-16 2010
 cancer 334, 1862, 2097, 2166, 2148
 cancer cachexia 876
 cancer genetics 1671
 cancer incidence 201
 cancer invasion 252
 cancer mortality 580, 1329
 cancer networks 1201
 cancer prevention 971
 cancer registries 188, 576, 1288
 Cancer Research UK 1830
 cancer risk 182, 572
 cancer screening 265
 cancer survival 1808
 cancer therapy 1599
 cancer vaccines 1358, 1421
 capecitabine 246, 820, 2129
 carboxylesterase 882
 carboxypeptidase G₂ 480
 carcinogenesis 562, 888
 carcinoma 15, 736
 carcinoma *in situ* 1934
 case-control studies, 594, 607, 1614, 1794, 2065, 2102
 case-mix adjustment 55
 CBS 838
 CCL2 2024
 CD1a 888
 CD44 1767
 CD4+ and CD8+ T-lymphocytes 651
 CD4+ T-cell subsets 913
 CD4+ CD25+ T cells 913
 CDC 342
 CDK4 2278
 CDKN2A/ARF 2278
 cDNA array 1193
 cDNA microarray 929
 cell adhesion 366, 2010
 cell culture 2166
 cell cycle 7
 cellular localisation 1702
 cellular retinoic acid binding protein 696
 central nervous system 747
 centrosome aberrations 389
 cervical cancer 41, 1800
 cervical neoplasias 601, 1794
 cervix carcinoma 449
 cetuximab 1063
 CHEK2 784
 chemoembolisation 1862
 chemoendocrine treatment 467
 chemoprevention 513
 chemoprophylaxis 867
 chemoprotection 294
 chemoradiation 284, 1372
 chemoradiotherapy 1341
 chemoradiotherapy 655, 1221
 chemotherapeutic agents 1430
 chemotherapy 36, 294, 334, 350, 459, 475, 673, 799, 1372, 1644, 1650
 chemotherapy response 147
 childhood 2042
 children 2084
 chimeric antibody 1069
 CHK2 784
 cholecystectomy 1307
 cholesterol 1785
 chromatin 1165
 chromosome 382
 chronic B-cell lymphocytic leukaemia (B-CLL) 1517
 chronic pain 225
 chronopharmacology 1684
cII gene 873
 circulating tumour cells 906
 circulating tumour DNA 2181
 cisplatin 246, 334, 475, 639, 827, 1084, 1149, 1352, 1611, 1636, 1684
 c-kit 1398
 classic Kaposi's sarcoma 188
 classification 847
 clinical trial 15, 1358
 coactivator 2286
 co-expression 1906
 cohort 176, 2070
 cohort studies 182, 194, 580, 995, 1302, 1326, 1803, 2042
 colon 736, 1078, 1310
 colon cancer 722, 985, 1307, 1655, 1803, 1846, 2240
 colorectal 60, 426
 colorectal adenoma 1193
 colorectal cancer 24, 430, 651, 832, 838, 1055, 1137, 1746, 1782, 1842, 2233
 colorectal cancer and anti-angiogenesis 350
 colorectal metastases 729
 colorectal neoplasms 259, 434
 combination 1006
 combination therapy 722
 comet 1626
 comfrey 873
 communication 1671
 comparative genomic hybridisation 935
 complement 895
 condom use 1388
 conformal radiotherapy 488
 corticosteroid 867

- cost 60
 Cox-2 2225
 CPT-11 882, 1055
 C-reactive protein 21, 625, 651
 Crohn's like reaction 1746
 CTL 72
 curative resection 21
 cutaneous squamous cell carcinoma 1326
 CXCR4 503
 cyclin D1 1581
Cyclin L1 770
 CYFRA 21 13
 CYP26 696
 cytokesines 921, 1450
 cytomegalovirus 747
 cytotoxic potential 1702
 cytotoxic T cells 1450
- Danish cancer patients 995
 Danish cancer register 995
 DCIS 162, 389
 DDS 1240
 death from all causes 2089
 delay 1959, 1971
 dendritic cells 1182
 denial 1393
 depression 1393
 deprivation 1279
 desmosome 2153
 detection rates 597
 dexamethasone 1084
 DGGE 1144
 diagnosis 236, 1959, 1971
 diet 971
 dietary fibre 1803
 diethylstilbestrol 1538
 differential expression 2249
 differentiation 751
 discordant sites 1288
 disease associations 1298
 disparities 1842
 distress 990
 diuretics 1302
 DLK1 1574
 DNA damage 334, 1524, 1626
 DNA damage response 784
 DNA double-strand break repair 1089
 DNA methylation 838, 1165
DNMT3L 1934
 docetaxel 15, 645, 827, 2129
 dose escalation 488
 dose intensity 832, 1019
 dose optimisation 1055
 dosimetry 298
 drug combinations 1063
 drug development 1837
 drug interaction 681
 drug resistance 80, 334, 1084, 1149
 ductal carcinoma *in situ* 1720
- E6 290
 E7 290
 early invasive colorectal carcinoma 1193
 Ebp1 140
- E-cadherin 985, 2018
 ECF 1650
 ECOG-ps 1834
 ecological studies 1279
 ECTO-NOX 690
 efficacy 1855
 EGF receptor 366
 EGFR 1069, 1737, 1846
 EGFR mutation 1922
 EGFRvIII 1069
 elastase 89
 ELF 2122
 endocrine tumours 94
 endometrial cancer 2059
 endometrium 1098
 endostatin 89, 729
 endothelium 503, 1493
 endothelin A receptor 2148
 energy balance 673
 England 194
 Ep-CAM 342, 882, 1767
 epidemiology 1276, 1302, 1326, 1782, 1785, 1803
 epidermal growth factor 1690
 epidermal growth factor receptor (EGFR) 334, 1063, 1110, 1341, 1877, 2266
epidermal growth factor receptor(EGFR) gene 1711
 epigenetics 1165
 epirubicin 1989
 eptophilone B 1006
 EPR effect 1240
 Epstein-Barr virus 1593
 ER 147
 ER α 2286
 ER β 2286
 ErbB receptors 140
 ErbB2 1421
 ERK1 2206
 ERK2 2206
 ethnic differences 1787
 ethnicity 1393
 etoposide 639, 1019, 1486
 Ewing tumours 705
 exosomes 305
 expression 376
 extra-nasal 1226
 Eysenck personality questionnaire-revised 2089
 EZH2 1754
- familial breast cancer 784
 familial thyroid carcinoma 1892
 family 1321
 fast recruitment 1679
 fat 971
 fatty acid 971
 FELV 1650
 fever therapy 421
 FGFR3 320
 FGFR4 320
 fibroblast growth factor 2, 705
 first-line chemotherapy 246
 FISH 770, 1253
 flat penile lesions 1388
 fluorescence *in situ* hybridisation 382
- FNAB 389
 folate 838, 1524
 followup 430
 follow-up study 1276
 food frequency questionnaire 971
 fried foods 2065
 fruit 1782, 2059
- γ -irradiation 320
 G-17 1581
 galectin-1 1188
 gamma-glutamyl transpeptidase 294
 garlic 1773
 gastric 2122
 gastric cancer 1051, 1130, 1273, 1759, 1767, 2190
 gastric carcinoma 1850
 gastric MALT lymphoma 312
 gastrin 1506
 gastrointestinal tumour 1117
 gefitinib 13, 1110, 1690, 1711, 1846
 gelonin 2004
 gemcitabine 445, 645, 815, 1084, 1352, 1684, 2139
 gene delivery 1414
 gene expression 1553, 1934, 2240
 gene expression profiles 1130
 gene expression profiling 1506, 1561, 1915
 gene-environment interaction 2039
 genetic 60
 genetic susceptibility 967
 genistein 80
 genotype 838
 geographic 1842
 German population 1159
 germline mutations 1144, 2278
 germline variation 784
 Glasgow osteosarcoma 1684
 GLC₄ 1459
 glioblastoma 1247
 glioma 747
 glucocorticoids 876
 GM-CSF 1019
 Golestan 176
 GPS 1834
 grade 613, 625
 Great Britain 587
 Greece 396
GRIM-19 1892
 groin nodes 222
 growth factors 921, 1247, 1467, 1506, 1720, 1899
 GRP 522
 GTL2 1574
 guidelines 867
- H2AX 1089
 haemoglobin beta (HBB) 2216
 hair 1837
 Hash-1 751
 HB-EGF 1737
 hDAB2IP 1117
- head and neck cancers 539, 913, 1046, 1341, 1819
 head and neck squamous cell carcinoma 770
 heat shock protein 499
Helicobacter pylori 1273, 1759
Helicobacter pylori eradication 312
 hepatitis-B virus 607, 935
 hepatitis-C virus 607, 935
 hepatocarcinogenesis 935
 hepatocellular carcinoma 252, 628, 929, 935, 1690, 1754, 1825
 hepatocyte growth factor 1506
 HER-2 1261, 1421
 HER-2/neu 72, 147, 1253
 hereditary non-polyposis colorectal cancer (HNPCC) 1746
 Hes-1 751
 HGF 1078
 HIF 94
 high-dose 5-FU and leucovorin 1013
 high-dose methotrexate 480
 high-dose therapy 47
 histology 847
 histone acetylation 1117
 histopathology 1366
 HIV 194
 HLA 1253
 HLA-related genes 967
hMLH1 396
hMSH2 396, 2286
 HNPCC 396, 2240, 2286
 homeobox gene 2233
 homocysteine 838
 hormone replacement therapy 1293
 hormone resistant 36
 hormone therapy 2049
 HOXB13 376, 2233
 HPV 290
 HPV type concordance 1388
 H-Ras 80
 hTERT 1942
 hTR 1942
 human papillomavirus (HPV) 265, 601, 891, 990, 1794, 1800, 2195
 human prostate cancer 2018
 Hürthle cell tumours 1892
 hWAPL 290
 hypericin 1406
 hypoxia 94, 350, 655, 1696
- IBDQ 1663
 ifosfamide 1626
 IGF-1 2097
IGF1 genotype 857
 IGF-1 levels 857
 IGF-1 receptor 2097
 IGFBP-3 1283
 IGFBP-6 1538
 IGF-I 1467
 IGF-II 1283
 IGF-II IGF-IR 1467
 ILF 2122

- image cytometry 389
 imaging 1046
 imatinib 1398
 imatinib mesylate 1881
 ImiDs 217
 immune responses 1358
 immunoglobulin heavy chain gene 312
 immunohistochemistry 113, 278, 743, 747, 1231, 1253, 1720, 1767, 2201
 immunostaining 942
 immunosurveillance 895
 immunotherapy 799, 843, 895, 1069, 1253, 1450
 imprinting 1574
in situ breast cancer 162
in situ hybridisation 743, 747, 2024
in vivo microscopy 729
 incidence 188
 India 601
 inducible gene expression 681
 inflammation 1268, 1927
 informed consent 1001
 inherited predisposition 2278
 inherited predisposition to breast cancer 1144
 inhibitor of apoptosis 120
 in-house cDNA microarray 1915
 inoperable pulmonary malignancy 1825
 insulin-like growth-factor-I (IGF-I) 1283
 insulin-treated diabetes 2070
 integration 2195
 integrin 1475
 integrin β 1 102
 intensity-modulated radiation therapy 1819
 interaction 1006
 interferon 1655
 interleukin 921
 interleukin-12 1450
 intestinal injury 294
 intracellular signalling 539
 intratumoral infusion 1414
 intravesical therapy 2145
 invasion 102, 1955
 invasive breast cancer 162
 invasive cervical cancer 891
 invasive ductal carcinoma 847
 Iran 176
 Iressa 1063
 irinotecan 15, 259, 722, 820, 1055, 1846, 1850, 2122
 irradiation 539
 Italy 188, 572

 Japanese 2089
 Japanese women 2102

 K562 1486
 Kaposi's sarcoma 572, 1467
 Ki-67 147
 kidney neoplasms 2266
 Ki-ras 405

 Korean 1273
 KP372-1 1899
 K-ras 1098

 large phase III clinical trials 1679
 large-core needle biopsy 231
 larynx 2185
 LCIS 162
 LENT SOMA 1663
 leucovorin 24
 leukaemia 1298, 2084
 levamisole 1655
 LHRH receptor 366
 limited resection 1033
 linkage 194
 lipolysis 876
 lipopeptide 1421
 lipoproteins 1406
 liposomes 1421
 liver cancer 572, 1307
 liver metastases 1825
 liver neoplasms 607
 liver transplantation 1862
LKB1 1126
 localised cancer 236
 LOH 236
 longitudinal 673
 longitudinal study 1834
 long-term 1800
 loss of heterozygosity (LOH) 30, 1517
 low-dose radiotherapy 1221
 LPAAT- β 1729
 luminescence 298
 lung cancer 131, 580, 743, 942, 1033, 1084, 1089, 1231
 lung neoplasms 1321
 lymph nodes 156
 lymphadenectomy 1051
 lymphangiogenesis 1720
 lymphatic metastasis/pathology 2201
 lymphocyte infiltration 1746
 lymphoma 1298, 1352, 1593

 M30-Apoptosense™ Elisa 532
 magnetic resonance 1599
 malignancy 570, 867
 malignant lymphoma 1349
 malignant melanoma 201
 mammaglobin 1948
 mammographic screening 1366
 mammography 156, 597, 949, 955, 961, 2102
 management 459
 MAPK pathway 2032
 maspin 1130, 1948
 mastectomy 55, 225
 maternal hormone levels 1787
 mathematical model 47
 matrix metalloproteinases 252, 2171
 MC-26 cells 1581
 MCP-1 2024
 MDM2 2097
 meat 1310
 medulloblastoma 359

 melanoma 662, 1398, 1499, 2249
 membrane vesicles 305
 menstruation 1098
 mesna 1636
 mesothelioma 580, 587
 messenger ribonucleic acid 259
 MET 1078, 1906
 meta-analysis 131, 430, 434, 935, 1033, 2049, 2076
 metastases 1690
 metastasis 449, 503
 metastatic 673, 2122
 metastatic breast cancer 475, 1989
 metastatic disease 634
 metastatic oesophageal cancer 2129
 metastatic pancreatic cancer 2139
 metastatic survival 1382
 methotrexate 24
 methotrexate toxicity 480
 methylation 760, 942, 1117, 1486, 1574
 methylation specific PCR 1117
 mice 1684
 microarray profiling gene expression pattern 80
 microarrays 376, 618, 1149, 1545
 micrometastases 222, 906
 micrometastasis 1948
 microsatellite instability (MSI) 1517, 1746, 2240
 mismatch repair 1137
 mitochondria 513, 1459
 mitochondrial DNA 1268
 mitochondrial proteins 1892
 mitogen-activated protein kinases 2266
 mitogenic signalling 921
 mitosis 1773
 mixture 2160
 MLPA 396
MO25 α 1126
 molecular targeted agents 799
 molecular therapy 1899
 monoclonal antibodies 1442
 mortality 241, 426, 587, 955
 motility 1955
 MS 838
 MT201 342
 MTHFR 838
 mucinous adenocarcinoma 259
 multiphoton laser scanning microscopy 729
 mutation 30, 1711, 2032, 2160
 MX2 1486
 myeloma 217
 myocardial infarction 1614

 nasopharyngeal cancer 967
 nasopharyngeal carcinoma 799, 1382
 natural history 156
 natural killer cell lymphoma 1226

 natural resistance 1711
 neoadjuvant chemoradiotherapy 1215
 neoadjuvant chemotherapy 147
 neoplasms 421, 570
 neovascularisation 553
 nested case-control study 1273
 neural system tumours 2278
 neuroblastoma 751, 1984
 neuroendocrine tumours 1506
 neuropilin-1 328
 neurotoxicity 832
 NF- κ B 711, 1137, 1593
 NK105 1240
 nonmelanocytic skin cancer 201
 nonseminoma 1934
 non-small-cell lung 15
 non-small-cell lung cancer 13, 459, 1038, 1834
 Notch 751
 Nottingham Prognostic Index 847
 novel treatments 217
 NSAIDs 1137
 NSCLC 775
 NSCLC cells 681
 nuclear and cytoplasmic staining 113

 occupation 1276
 Octreotide 1493
 oesophageal cancer 176, 284
 oesophageal neoplasms 2065
 oestradiol 547
 old age 1221
 older women 1794
 oleate 971
 olfaction 1611
 oligonucleotide array 2249
 oligonucleotide microarray 1130
 oncogenes 770, 2190
 oncogenic viruses 743
 oncology 421
 ongoing mutation 312
 oral chemotherapy 1989
 oral neoplasms 2065
 oral squamous cell carcinoma 30, 2181
 oral vinorelbine 1989
 organ metastasis 1746
 osteoclast 1531
 osteosarcoma 1358
 ovarian 60
 ovarian adenocarcinoma 2024
 ovarian cancer 113, 271, 278, 305, 1026, 1149, 1475, 1729, 1737, 1927
 ovarian neoplasm 895
 ovarian surface epithelium 1927
 overweight 2042
 oxaliplatin 259, 655, 832, 1644
 oxidative stress 1696

 p21 131, 284
 p53 30, 284, 1089, 1137, 2097
 P53 gene 434, 1144
 p53 status 2114

- p53R2 284
 paclitaxel 320, 634, 639, 1240
 paediatric 1626
 palliative treatment 1038
 pancreas 94, 1372
 pancreatic cancer 21, 89, 405, 445, 921, 971, 1307, 2076
 pancreatic carcinoma 2225
 papillary 1545
 papillary thyroid cancer 2216
 Parkinson's disease 201
 parotid gland 539
 patient 1959
 patient motivations 1001
 patients' preferences 807
 PDGF-R 1398
 pegylated liposomal doxorubicin 628
 PEI 1862
 pelvic radiotherapy 1663
 peptide 328
 perfusion 1406
 peritoneal fluid 1737
 permeability 1406
 peroxisome proliferator-activated receptor 113
 Peutz-Jeghers syndrome 1126
 PgR 147
 pharmacodynamic 1837
 pharmacogenomics 259
 pharmacokinetics 820, 1006, 1636, 1855, 2004
 pharyngeal neoplasms 2065
 phase I 820, 1636
 phase I study 815, 2139
 phase II 15, 445, 628
 phase I/II cancer clinical trials 1001
 phase III trial 488
 phosphatidic acid 1729
 phosphorylation 2206
 photochemical internalisation 2004
 photodynamic therapeutic agent 1702
 photodynamic therapy 298, 1406, 1442, 2004
 PI3-Akt 681
 picropodophyllin 1467
 plakoglobin 2153
 plasminogen activation 1475
 platinum pretreatment 1019
 PNA 405
Pneumocystis pneumonia 867
 polycomb group protein 1754
 polymer micelles 1240
 polymorphisms 30, 2039, 2262
 pooled analysis 1288
 population-based 182, 995
 population-based study 1293
 population-based survival 1808
 positron emission tomography 655
 post mastectomy pain 225
 post-Chernobyl 1545
 post-operative 1372
 precounselling needs 1671
 prediction 434, 587, 613
 prediction response 618
 predictive marker 2114
 predictivity 1261
 pregnancies 167
 pre-hospital 1971
 premenopausal 467
 premenopausal breast cancer 857
 prescriptions 594
 primary care 1959
 proband 1321
 prognosis 271, 278, 434, 449, 576, 618, 847, 1026, 1231, 1906, 1955, 2181, 2206, 2225
 prognostic factors 13, 131, 662, 1382, 1767
 programmed cell death 120
 progression 2018
 proliferation 751, 1467, 1493, 1506, 1881
 promoter hypermethylation 775, 2190
 prospective cohort study 857, 2089
 prospective study 1283, 1782
 prostate 376, 426, 503, 2166
 prostate cancer 36, 140, 320, 366, 488, 1159, 1538, 1819, 2171
 prostrate cancer 499
 proteasome inhibitors 217
 proteasome proteolysis 711
 protein biosynthesis 2266
 protein degradation 711
 protein tyrosine kinases 1906
 proteolysis-inducing factor (PIF) 711
 PSA 488
 PTEN 1711
 pTNM 847
 public understanding 265
 pyrrolizidine alkaloid 873
 quality of life 668, 990, 1869
 quantitative RT-PCR 532
 quercetin 499
 R116010 696
Rab1a gene 1915
 race 2084
 Rad51 1089
 radiation 125
 radiation therapy 1614
 radiation toxicity 488
 radical radiotherapy 41
 radiofrequency 1825
 radioresistance 2185
 radiosensitisation 125, 815
 radiotherapy 449, 459, 799, 1038, 1201, 1372, 2114
 raltitrexed 445
 Raman spectroscopy 2166
 randomisation 807
 randomised controlled trials 811
 RAS 131, 2032
 RAW 264.7 1531
 reactive oxygen species 1759
 real-time PCR 405, 547, 775, 2249
 rearrangements 396
 receptors 1720
 receptor specificity 2148
 record linkage 1298, 1307
 rectal cancer 655, 1209, 1215, 2114
 rectal carcinoma 1209
 rectum 1310
 recurrences 430, 1026
 redox state 690
 referral 1959, 1971
 refractory 1352
 regulatory T cells (T_{reg}) 913
 relapsed 1352
 remnant stomach cancer 562
 renal cell cancer incidence 1302
 renal cell carcinoma 843, 1421, 1825, 2010
 renal development 2010
 renal transplant 572
 replication errors positive phenotype (RER+) 1517
 research 613
 research spending 241
 resection 1372
 resveratrol 513
 retinoic acid 696
 risk 594, 1302, 1349
 risk factors 1273, 2042, 2065
RNASEL 1159
 RON 1906
 RUNX3 562
 rye 1803
 S-1 2139
 safety 1855
 saline hydration 1636
 salvage chemotherapy 1850
 salvage surgery 430
 salvage therapy 1019
 sarcoma 2004
 SCID mice 72
 SCLC 522
 screening 55, 156, 597, 949, 955, 1800
 screening frequency 961
 screening interval 961
 second primary 570
 secondary care 1959, 1971
 secondary cytoreductive surgery 1026
 second-line chemotherapy 15
 segmentectomy 1033
 selective chemotherapy 499
 seminoma 1934
 semiquantitative PCR 278
 sentinel lymph node biopsy (SLNB) 662
 sentinel lymph node biopsy/methods 2201
 sequential hemi-body irradiation 1984
 sequential hormonal therapy 1621
 serine proteases 760, 2171
 serological analysis of recombinant cDNA expression libraries 929
 serous papillary uterine cancer 1561
 serum biomarker 2018
 serum DNA 2181
 sex hormone 1877
 sFGFR 320
 shortening 668
 short-term preoperative radiotherapy 1209
 signalling 2153
 signalling pathways 1690
 singlet oxygen 298
 siRNA 290
 skeletal metastases 1869
 skin 570
 skin cancer 499
 small-area geography 1279
 small-cell lung carcinoma 1553
 small-molecule therapy 1922
 smear test 990
 smell 1611
 smoking 426, 1321
 smoking tobacco 1326
 smoky coal exposure 1321
 SNAIL 252, 985
 snuff dipping 1326
 social deprivation 631
 sociodemographic 1971
 socioeconomic status 1279
 solid tumours 1855
 soluble vascular endothelial growth factor receptor-1 553
 SOM230 1493
 somatostatin receptors 1493
 SPARC 942
 SP-D 522
 SP-G 522
 spheroid 882
 splicing variants 1942
 spontaneous neoplasm regression 421
 squamous cell 570
 squamous cell carcinoma (HNSCC) 1046, 1341
 SSCP 2024
 SSI 389
 ST14 278
 stage 625
 stage I non-seminoma 2107
 Stat1 1149
 statin 1593
 statistical methods 576
 stearate 971
 stem cell 2160
 stomach cancer 1307
 stomach neoplasms 827
STRAD α 1126
 subsequent malignancy 1288
 suicide 995
 surgery 459, 1209
 surgical decision-making 631
 surrogate 955
 survival 21, 131, 459, 625, 651, 1279, 1329, 1767, 1834, 2089
 survival analysis 576

- survival signals 705
 survivin 212, 271, 359
 Survivin isoforms 359
 survivin-2B 212
 survivin-DEX3 212
 surviving 2225
 susceptibility 784
 systematic review 131, 434

 T lymphocytes 305
 TADG-15 278
 tamoxifen 547, 1098, 1614
 tandem base substitution 873
 targeted agent 1855
 targeted therapy 7
 targeted treatment 217
 taxonomy 613
 TCF4 2233
 telomerase 1881, 1942
 testicular cancer 1934
 testicular germ cell cancer 1787
 testicular neoplasm 1785
 Testisin 760
 TFPI-2 775
 thalidomide 217
 therapeutic trials 1599
 therapy 985
 thermal ablation 1825
 thioredoxin 350
 thromboembolism 1349
 thymidine phosphorylase 1696
 thyroid 1545
 thyroid cancer 1892
 time since births 167
 tissue microarray analysis 770

 tissue microarrays 743
 tongue squamous cell carcinoma 1915
 topoisomerase 1486
 toremifene 1098
 toxicity 1663
 TRAIL 736, 1430
 TRAIL receptor 1 1430
 transactivation 2286
 transformation 522, 1078
 transgenic rat 873
 transitional cell carcinoma 645, 2262
 translocation 382
 trastuzumab 342, 1261
 treatment 1226
 trends 1201
 trial 949
 trial registration 811
 TSA 751
 tumorigenesis 212, 1268
 tumortropic behaviour 1406
 tumour 421
 tumour antigens 929
 tumour lysates 72
 tumour necrosis factor alpha 1690
 tumour progression 366, 2249
 tumour size 21
 tumour suppressor 760
 tumour suppressor genes 2190, 2216
 tumour-associated NADH oxidase 690

 tumour-immune escape 1188
 turkmen 176
 type 2195
 type-II diabetes 2076
 tyrosine kinase 1922
 tyrosine kinase inhibitor 1877
 typhostins 294

 UFT 827
 Uganda 1808
 UK Europe 1329
 ultrasound 231, 499
 undescended testes 1787
 undifferentiated thyroid cancer 1110
 United Kingdom 1794
 untreated phase III 1650
 urban-rural differences 2084
 urokinase plasminogen activator receptor 1475
 uveal melanoma 2032

 Vaizey 1663
 validation 668
 variation 55
 vascular endothelial growth factor 553
 vascular endothelial growth factor A 1182
 vascular endothelial growth factor receptor-2 553
 vascular invasion 1754
 vasopressin 522
 VDR 985
 vegetables 1782, 2059

 VEGF 328, 1467, 1531, 1696
 VEGFR1 1531
 VEGFR2 1531
 vinorelbine 634
 viral hepatitis 1268
 viral load 891, 2195
 virus dissemination 1414
 vitamin D 985
 volunteer studies 2148
 VPA 751
 vulval cancer 222
 vulval squamous cell carcinoma 102

 waiting times 1201
 wedge resection 1033
 weekly vinorelbine 1013
 Western blot analysis 532
 whole grains 1803
 wild-type *K-ras* 1310

 xenografts 722
 Xeroderma Pigmentosum Group C (XPC) 2262
 XIAP 532
 XR5944 722

 years of life lost 241

 ZD1839 13, 125
 ZD 4054 2148
 zinc- α_2 -glycoprotein 876